logo
  

Ryanair April Passengers Up 8% YoY

Ryanair Holdings plc (RYA.L,RYAAY) reported guests of 17.3 million for the month of April, 2024, compared to 16.0 million, a year ago, an increase of 8%. Load factor was 92% compared to 94%, prior year, down 2 percentage points. The airline operated over 98,400 flights in April. Almost 700 flights were cancelled due to Israel/Gaza conflict and over 340 flights cancelled due to the French ATC strike.

For the rolling period, guests were 185.0 million, an increase of 9% from prior year. Load factor was 93%, a decline of 1 percentage point.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft has launched a new category of Windows PCs designed for Artificial Intelligence (AI) that are slated to be the fastest and most intelligent Windows PCs ever built. The Copilot+ PCs come with built-in AI hardware and will support AI features across the operating system. Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings...

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT